Actively Recruiting
The Effect of Dapagliflozin on Patients With Cardiomyopathy
Led by May Mohamed Abdalla · Updated on 2025-08-22
100
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
Sponsors
M
May Mohamed Abdalla
Lead Sponsor
C
Cairo University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This randomized controlled trial evaluates the efficacy and tolerability of early initiation of dapagliflozin in adult patients hospitalized with acute heart failure (AHF). The study aims to assess the effect of dapagliflozin on pulmonary congestion as measured by lung ultrasound (LUS), length of hospital stay, and cardiac and renal biomarkers. A total of 100 patients will be randomized into two groups: one receiving dapagliflozin plus diuretics and the other receiving diuretics alone. Key outcomes include the reduction of extravascular lung water (assessed by B-lines in LUS), improved diuretic response, changes in NT-proBNP, sST2, CA-125, and NGAL levels, and incidence of acute kidney injury. The study will be conducted at the Cardiology and ICU departments at Kasr Al Ainy Hospital, Cairo University
CONDITIONS
Official Title
The Effect of Dapagliflozin on Patients With Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Diagnosed with acute heart failure based on 2022 ACC/AHA or 2021 ESC guidelines requiring hospitalization or emergency visit
- Elevated natriuretic peptide levels
- Includes heart failure with reduced, mildly reduced, or preserved ejection fraction
- Planned treatment with intravenous diuretics
You will not qualify if you...
- Diagnosis of type 1 diabetes mellitus
- Current urinary tract or genital infection
- Presence of hypovolemia
- Diabetic ketoacidosis
- Serum glucose below 80 mg/dL at enrollment
- Systolic blood pressure below 90 mmHg at enrollment
- History of hypersensitivity to any SGLT2 inhibitor
- Pregnant or breastfeeding women
- Severe primary valvular lesion requiring intervention
- Severe liver impairment (Child-Pugh class C)
- Estimated glomerular filtration rate below 25 mL/min/1.73 m²
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cairo University
Cairo, Egypt
Actively Recruiting
Research Team
M
May M Abdalla, Senior teaching assistant
CONTACT
A
Ahmed M Kamal, Lecturer of Cardiovascular
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here